NCT05221736

Brief Summary

Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 7, 2022

Completed
27 days until next milestone

First Posted

Study publicly available on registry

February 3, 2022

Completed
3 months until next milestone

Study Start

First participant enrolled

May 1, 2022

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2023

Completed
Last Updated

February 3, 2022

Status Verified

January 1, 2022

Enrollment Period

1.2 years

First QC Date

January 7, 2022

Last Update Submit

January 23, 2022

Conditions

Warthin's Tumor of Parotid Gland

Outcome Measures

Primary Outcomes (1)

  • Primary (main):

    Rate of curability in each group

    1 year

Secondary Outcomes (1)

  • Secondary (subsidiary):

    1 week

Study Arms (1)

Warthin tumor in parotid tumor

EXPERIMENTAL

Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.

Procedure: Ultrasound-Guided Ethanol Sclerotherapy (UGES)

Interventions

Ultrasound-Guided Ethanol Sclerotherapy (UGES)PROCEDURE

Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.

Also known as: Surgical excision
Warthin tumor in parotid tumor

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All new cases presented with benign parotid cyst and diagnosed as Warthin tumour in the parotid gland.

You may not qualify if:

  • Other Parotid gland tumours e.g. solid tumours, malignant tumours and other suspicious tumours.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university

Asyut, Egypt

RECRUITING

Study Officials

  • Hamdan S. Abbas

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Kerolos N. Hosny

CONTACT

+201033216963kerolosnashaat93@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant lecturer

Study Record Dates

First Submitted

January 7, 2022

First Posted

February 3, 2022

Study Start

May 1, 2022

Primary Completion

July 31, 2023

Study Completion

October 31, 2023

Last Updated

February 3, 2022

Record last verified: 2022-01

Data Sharing

IPD Sharing
Will share

age, sex , clinical diagnosis

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
3 years
Access Criteria
age, sex , clinical diagnosis

Locations

EG(1)